Table S4: Number of events, follow-up time, incidence rates, and hazard ratios for all study outcomes based on an inverse probability of treatment weighted population of approximately 15% warfarin users and 85% non-users using the full cohort of 12,284 patients and as treated analyses where patients were censored 30 days after their drug supply ran out.

Outcome	Analysis	Exposure group	Number of events	Follow-up time (years)		Incidence rate (per 100 person-years)	Hazard ratio (95% CI)
				Mean ± SD	Median		
All-cause mortality	AT30 [a]	Warfarin	275	0.41 ± 0.47	0.23	33.0	0.82 (0.69-0.97)
		No warfarin	4006	1.20 ± 1.10	0.85	31.9	
Cardiovascular mortality	AT30 [a]	Warfarin	131	0.41 ± 0.47	0.23	16.1	0.86 (0.67-1.11)
		No warfarin	2064	1.23 ± 1.14	0.86	16.3	
Ischemic stroke	AT30 [a]	Warfarin	23	0.40 ± 0.48	0.22	2.8	0.73 (0.41-1.31)
		No warfarin	494	1.31 ± 1.21	0.91	3.7	
Hemorrhagic stroke	AT30 [a]	Warfarin	24	0.40 ± 0.48	0.22	2.9	2.74 (1.16-6.44)
		No warfarin	170	1.34 ± 1.23	0.95	1.2	
Any stroke or stroke death	AT30 [a]	Warfarin	51	0.45 ± 0.54	0.25	5.9	0.97 (0.60-1.56)
		No warfarin	650	1.18 ± 1.12	0.80	5.2	
Gastrointestinal bleeding	AT30 [a]	Warfarin	85	0.40 ± 0.47	0.22	10.4	1.52 (1.00-2.29)
		No warfarin	774	1.26 ± 1.18	0.87	6.0	

Composite outcome[b]	AT30 [a]	Warfarin	328	0.43 ± 0.49	0.24	41.1	0.92 (0.79-1.07)
		No warfarin	4219	1.09 ± 1.03	0.75	37.1	

AT30 – as treated, CI – confidence interval, ITT – intention to treat, SD – standard deviation

[a] Stratified Cox by year when atrial fibrillation was diagnosed.

[b]Composite outcome includes any stroke or stroke death, gastrointestinal bleeding, and all-cause mortality.